SOURCE: Apogee Technology, Inc.

October 03, 2007 09:00 ET

Professor Hans Wigzell Joins Apogee's Scientific Advisory Board

NORWOOD, MA--(Marketwire - October 3, 2007) - Apogee Technology, Inc. (AMEX: ATA), a biotechnology company focusing on the development of intradermal delivery systems for the administration of drugs and vaccines, announced today that Professor Hans Wigzell has joined Apogee's Scientific Advisory Board.

Hans Wigzell, a Professor of Immunology at Karolinska Institutet (Sweden), also serves as a Chief Scientific Advisor to the Swedish Government and is on the scientific advisory boards of several biotechnology companies. Professor Wigzell previously served as President of the Karolinska Institutet (1995-2003), Chairman of the Nobel Committee (1990-1992), and a Chairman of the Nobel Assembly (2000). His previous affiliations have also included positions as Chairman of the WHO-UNAIDS Vaccine Advisory Committee, Secretary-General of the Swedish Institute for Infectious Disease Control, and Director General of the National Bacteriological Laboratory in Stockholm.

Professor Wigzell, who holds both M.D. and D.Sc. degrees, is an elected member of the Royal Swedish Academy of Sciences, the Royal Swedish Academy of Engineering Sciences, the Finnish Society of Sciences and Letters, the Danish Academy of Sciences and Letters, EMBO, and Academia Europea. In addition, Professor Wigzell is an honorary member of the American Society for Immunology, has received numerous awards, published over 600 articles and is a member of the editorial boards of several international journals.

"I am looking forward to working with the team in this emerging biotech company and contributing to the development of their innovative vaccine delivery systems," said Professor Wigzell.

Dr. Alexander K. Andrianov, Apogee's Vice President of Research and Development, said: "We are extremely delighted with Professor Wigzell's decision to join our scientific advisory board. Professor Wigzell is an eminent immunologist and one of the most creative and prolific scientists in the world. His insight and advice will be invaluable for the development of our intradermal immunization systems."

About Apogee Technology, Inc.

Apogee Technology, Inc. is a biotechnology company developing proprietary systems for the delivery of pharmaceutical agents into the skin for the treatment and prevention of local and systemic conditions. The Company's PyraDerm™ delivery system incorporates structured solid-state formulations designed to penetrate the outer layer of the skin and then release the agent in a controlled manner. The Company is also developing and commercializing sensors and sensor systems with a specialized focus on health monitoring. For more information please visit our web site at: http://www.apogeebio.com.

PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate," "may," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve the design, development and production efforts of our PyraDerm™ and Sensilica® technologies, known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB, as amended, for the year ended December 31, 2006 and10-QSB for the quarter ended June 30, 2007.

Contact Information

  • Apogee Investor Contact:
    Kelly Black
    Premier Funding & Financial Marketing
    480-649-8224
    Email Contact